Darapladib for the treatment of cardiovascular disease
Expert Review of Cardiovascular Therapy 13(1): 33-48
Article 2014 English
Authors
CC
Carlos M. Campos
PS
Pannipa Suwannasom
WK
Wolfgang Köenig
Abstract
1 min read
Elevated levels of phospholipase A2 have been linked to atherosclerotic plaque progression, instability via promoting inflammation and subsequent acute coronary events. Epidemiological studies have demonstrated the correlation between elevated levels associated phospholipase A2 and cardiovascular events. Therefore, specific inhibition of lipoprotein-associated phospholipase A2 with darapladib has been tested as a therapeutic option for atherosclerosis. The aim of this profile is to review the physiologic aspects of lipoprotein-associated phospholipase A2 and to revisit the clinical evidence of darapladib as therapeutic option for atherosclerosis.
Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White, Patrick W. Serruys, Philippe Gabríel Steg, Judith S. Hochman, Aldo P. Maggioni, Christoph Bode, Donald W. Weaver, Joel L. Johnson, Greg Cicconetti, Mary Ann Lukas, Elizabeth Tarka, Christopher P. Cannon
Patrick W. Serruys, Héctor M. García‐García, Paweł Buszman, Paul Erné, Stefan Verheye, Michael Aschermann, Henrikus Duckers, Øyvind Bleie, Dariusz Dudek, Hans Erik Bøtker, Clemens von Birgelen, Don D'Amico, Tammy Hutchinson, Andrew Zambanini, Frits Mastik, Gerrit-Anne van Es, Antonius F.W. van der Steen, D. Geoffrey Vince, Peter Ganz, Christian W. Hamm, William Wijns, Andrew Zalewski
Michelle L. O’Donoghue, Eugene Braunwald, Harvey D. White, Dylan P. Steen, Mary Ann Lukas, Elizabeth Tarka, Philippe Gabríel Steg, Judith S. Hochman, Christoph Bode, Aldo P. Maggioni, KyungAh Im, Jennifer B. Shannon, Richard Y. Davies, Sabina A. Murphy, Sharon Crugnale, Stephen D. Wiviott, Marc P. Bonaca, David F. Watson, W. Douglas Weaver, Patrick W. Serruys, Christopher P. Cannon
Discussion(0)
No comments yet. Be the first to comment.